

# Anna K Å-verby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/743035/publications.pdf>

Version: 2024-02-01

44  
papers

1,755  
citations

361296

20  
h-index

302012

39  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2201  
citing authors

#	ARTICLE	IF	CITATIONS
1	Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. <i>Infectious Diseases</i> , 2022, 54, 283-291.	1.4	17
2	Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welton, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>Eur Urol.</i> 2022;81:285-93. <i>European Urology</i> , 2022, 81, e124-e125.	0.9	4
3	A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>European Urology</i> , 2022, 81, 285-293.	0.9	40
4	Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welton, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>Eur Urol.</i> 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients. <i>European Urology</i> , 2022, 81, e143-e144.	0.9	1
5	Molecular Organisation of Tick-Borne Encephalitis Virus. <i>Viruses</i> , 2022, 14, 792.	1.5	19
6	Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. <i>MBio</i> , 2022, 13, e0089222.	1.8	14
7	Chapter 4: Pathogenesis of TBE with a focus on molecular mechanisms. <i>Tick-borne Encephalitis - the Book</i> , 2022, , .	0.0	0
8	PKR kinase directly regulates tau expression and Alzheimer's disease-related tau phosphorylation. <i>Brain Pathology</i> , 2021, 31, 103-119.	2.1	17
9	COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 209.	0.7	8
10	BAF45b Is Required for Efficient Zika Virus Infection of HAP1 Cells. <i>Viruses</i> , 2021, 13, 2007.	1.5	2
11	Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 6761.	5.8	47
12	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. <i>BMC Research Notes</i> , 2021, 14, 440.	0.6	21
13	Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. <i>IScience</i> , 2021, 24, 103469.	1.9	17
14	The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection. <i>Journal of Neuroinflammation</i> , 2020, 17, 284.	3.1	8
15	N-glycosylation in the Pre-Membrane Protein Is Essential for the Zika Virus Life Cycle. <i>Viruses</i> , 2020, 12, 925.	1.5	20
16	Antiviral Activity of Benzavir-2 against Emerging Flaviviruses. <i>Viruses</i> , 2020, 12, 351.	1.5	10
17	Revealing new tick-borne encephalitis virus foci by screening antibodies in sheep milk. <i>Parasites and Vectors</i> , 2020, 13, 185.	1.0	25
18	Model System for the Formation of Tick-Borne Encephalitis Virus Replication Compartments without Viral RNA Replication. <i>Journal of Virology</i> , 2019, 93, .	1.5	13

#	ARTICLE	IF	CITATIONS
19	Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. <i>Antiviral Research</i> , 2019, 164, 23-51.	1.9	248
20	Characterizing the cellular attachment receptor for Langkat virus. <i>PLoS ONE</i> , 2019, 14, e0217359.	1.1	6
21	Quantitative Proteomics of Uukuniemi Virus-host Cell Interactions Reveals GBF1 as Proviral Host Factor for Phleboviruses. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2401-2417.	2.5	12
22	Viperin Restricts Zika Virus and Tick-Borne Encephalitis Virus Replication by Targeting NS3 for Proteasomal Degradation. <i>Journal of Virology</i> , 2018, 92, .	1.5	79
23	Cell-type- and region-specific restriction of neurotropic flavivirus infection by viperin. <i>Journal of Neuroinflammation</i> , 2018, 15, 80.	3.1	44
24	Viperin Targets Flavivirus Virulence by Inducing Assembly of Noninfectious Capsid Particles. <i>Journal of Virology</i> , 2018, 92, .	1.5	41
25	The interplay between viperin antiviral activity, lipid droplets and JunÅ— mammarenavirus multiplication. <i>Virology</i> , 2018, 514, 216-229.	1.1	21
26	Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells. <i>Nature Communications</i> , 2018, 9, 4845.	5.8	148
27	The Role of Viperin in Antiflavivirus Responses. <i>DNA and Cell Biology</i> , 2018, 37, 725-730.	0.9	25
28	Tick-Borne Flaviviruses and the Type I Interferon Response. <i>Viruses</i> , 2018, 10, 340.	1.5	38
29	Correlation of Severity of Human Tick-Borne Encephalitis Virus Disease and Pathogenicity in Mice. <i>Emerging Infectious Diseases</i> , 2018, 24, 1709-1712.	2.0	15
30	Cellular requirements for ironâ—sulfur cluster insertion into the antiviral radical SAM protein viperin. <i>Journal of Biological Chemistry</i> , 2017, 292, 13879-13889.	1.6	35
31	Human Tick-Borne Encephalitis and Characterization of Virus from Biting Tick. <i>Emerging Infectious Diseases</i> , 2016, 22, 1485-1487.	2.0	12
32	The role of the poly(A) tract in the replication and virulence of tick-borne encephalitis virus. <i>Scientific Reports</i> , 2016, 6, 39265.	1.6	35
33	Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections. <i>Cytokine and Growth Factor Reviews</i> , 2016, 30, 95-101.	3.2	17
34	Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects. <i>Journal of Neuroinflammation</i> , 2016, 13, 277.	3.1	116
35	High-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection. <i>Journal of Biomolecular Screening</i> , 2016, 21, 354-362.	2.6	14
36	Type I Interferon response in olfactory bulb, the site of tick-borne flavivirus accumulation, is primarily regulated by IPS-1. <i>Journal of Neuroinflammation</i> , 2016, 13, 22.	3.1	57

#	ARTICLE	IF	CITATIONS
37	Generation of Mutant Uukuniemi Viruses Lacking the Nonstructural Protein NSs by Reverse Genetics Indicates that NSs Is a Weak Interferon Antagonist. <i>Journal of Virology</i> , 2015, 89, 4849-4856.	1.5	38
38	Tick-Borne Encephalitis Virus Sequenced Directly from Questing and Blood-Feeding Ticks Reveals Quasispecies Variance. <i>PLoS ONE</i> , 2014, 9, e103264.	1.1	34
39	Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. <i>Cellular Microbiology</i> , 2014, 16, 834-848.	1.1	94
40	Type I Interferon Protects Mice from Fatal Neurotropic Infection with Langat Virus by Systemic and Local Antiviral Responses. <i>Journal of Virology</i> , 2014, 88, 12202-12212.	1.5	70
41	Hiding from intracellular pattern recognition receptors, a passive strategy of flavivirus immune evasion. <i>Virulence</i> , 2011, 2, 238-240.	1.8	23
42	Tick-Borne Encephalitis Virus Delays Interferon Induction and Hides Its Double-Stranded RNA in Intracellular Membrane Vesicles. <i>Journal of Virology</i> , 2010, 84, 8470-8483.	1.5	161
43	Generation and Analysis of Infectious Virus-Like Particles of Uukuniemi Virus ( <i>Bunyaviridae</i> ): a Useful System for Studying Bunyaviral Packaging and Budding. <i>Journal of Virology</i> , 2006, 80, 10428-10435.	1.5	65
44	Chapter 4: Pathogenesis of TBE with a focus on molecular mechanisms. <i>Tick-borne Encephalitis - the Book</i> , 0, , .	0.0	0